Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 754

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 754
---
 to fifty percent ( 50%) of future offerings for one yearfollowing the closing of the offering. In addition, the Company agreed not to enter into an equity line of credit or similar agreement, without the consent of the majority of the holders of the preferred shares. The transactions contemplated by the October SPA closed on October 10, 2024. On June 28, 2024, the Company entered into a securities purchase agreement for the issuance of 81,944Company Common Shares at a purchase price of $ 9.60per share. The offering closed on July 1, 2024. Investors also received unregistered warrants to purchase up to 81,944Company Common Shares at an exercise price of $ 9.60per share. These warrants are exercisable upon issuance and will expire five years from the date of issuance. The offering resulted in gross proceeds of $ 786,660. The net proceeds were used for working capital and general corporate purposes. H.C. Wainwright & Co., LLC served as the exclusive placement agent for the offering, or the Placement Agent. The Company agreed to pay the Placement Agent a cash fee of 7.0% of the gross proceeds, a management fee of 1.0% of the gross proceeds, and $ 50,000for accountable expenses. Additionally, the Company issued to the Placement Agent warrants to purchase up to 5,736Company Common Shares at an exercise price of $ 12.00per share. These warrants are exercisable from the date of issuance until five years from the commencement of sales in the offering. On March 20, 2024, the Company entered into a securities purchase agreement, or the Purchase Agreement, providing for the issuance in a registered direct offering of 175,000Company Common Shares at a purchase price of $ 10.00per share that closed on March 22, 2024. In addition, pursuant to the Purchase Agreement, the investors received unregistered warrants, or the Common Warrants, to purchase up to an aggregate of 87,500Company Common Shares at an exercise of $ 10.00per share in a concurrent private placement. The Common Warrants were immediately exercisable upon issuance and will expire five years following the date of issuance. The Company has also agreed that from the date of the Purchase Agreement until one year after the closing date of the offering, the Company shall not enter into an agreement to effect any issuance by the Company or any of the Company’s subsidiaries of Company Common Shares or